Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445911 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Kaneq Bioscience Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 4
- Study locations
NCT02445911 is a Phase 1 study of Diabetes Mellitus, Type 2 that has completed, run by Kaneq Bioscience Limited. The registered enrollment target is 81 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02445911, a Phase 1 study of Diabetes Mellitus, Type 2, has completed, sponsored by Kaneq Bioscience Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KQ-791
Study Locations (4)
Florida
- Clinical Pharmacology of Miami, Inc. - Miami
- Orlando Clinical Research Center - Orlando
Arizona
- Celerion - Tempe
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02445911
The ClinicalTrials.gov registry entry for NCT02445911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Kaneq Bioscience Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02445911 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Arizona, Nebraska.
Frequently Asked Questions
What is clinical trial NCT02445911 about?
NCT02445911 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus". This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
What is the current status of trial NCT02445911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2015-06. Estimated completion is 2016-02.
What conditions does trial NCT02445911 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02445911?
The interventions under investigation include: Placebo (DRUG), KQ-791 (DRUG).
Who is sponsoring clinical trial NCT02445911?
This trial is sponsored by Kaneq Bioscience Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02445911 being conducted?
This trial has 4 study locations across Arizona, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.